Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
about
The concept of treatment-free remission in chronic myeloid leukemiaKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsImatinib in chronic myeloid leukemia: an overviewCurrent status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemiaImmune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceDownregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report.Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.Myeloid derived suppressor cells in chronic myeloid leukemia.Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.Re-emergence of interferon-α in the treatment of chronic myeloid leukemiaEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.Molecular monitoring.How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.Discontinuation of tyrosine kinase therapy in CML.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Minimal Residual Disease Eradication in CML: Does It Really Matter?New Methodologies in the Molecular Monitoring of CML.Present and future of molecular monitoring in chronic myeloid leukaemia.Molecular monitoring of chronic myeloid leukemia: present and future.Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments.Hepatitis B reactivation in patients receiving targeted therapies.Treatment-free remission in patients with chronic myeloid leukemia.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.What challenges remain in chronic myeloid leukemia research?Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
P2860
Q26748733-963DFE0C-960C-4E72-8509-0A6B7A954537Q26849792-FA94E588-6C8C-468A-B9DD-450E6F93843EQ26865086-39F0B128-7F23-4C74-9DB0-F5765C59E3D2Q27027369-B83AFE2E-16F1-45ED-8656-337EC329CCFEQ33593877-3BFFF2C8-0CA8-4406-B322-E56A68527184Q34022125-128CA62F-1F41-4F02-B3C1-7235DA6CF5A5Q34109784-F74A0E4C-6D4E-4067-9679-A34C3F203364Q34163496-B0C31177-D2B0-4FC2-A4F4-FED16329B46AQ34170236-58591A4D-C042-4D1B-9AA9-E2D8AB6D4B78Q34272962-86D1DBE3-C321-48DE-9F9E-A0006149E357Q34792645-C6F9CB90-16A5-480C-8CC7-F043C8220AE2Q35609094-50332E1B-9F4A-45C0-9495-81678124A3EBQ36316309-8734B935-287C-49F1-96EA-85B09217E065Q36989407-14C30582-5927-43C4-A722-DF64A5F7E3BAQ37026032-6C469EFA-3261-43B1-AE03-C50A74934801Q37237918-2FF0D759-7F1A-497F-B2EE-2B77AA5A2B28Q37629012-D5F1E536-72F4-4C65-909E-4902219BBC4CQ37696776-C621A1B7-4118-421D-B4B9-244A41C2B19CQ37719627-1FA9611A-F90E-4850-9C1E-8D29D45F5993Q38148233-DF19986C-6FB2-4F10-ACCE-C35F647439C9Q38176284-AC20D441-107E-469C-A2E0-64F2E2AF8F53Q38206284-26DC9037-DF7C-405B-883B-3C8B5F9A6E43Q38233370-A2FB1ECC-301A-4B13-AB62-BAC1C8BBFE08Q38392692-8956459E-FB33-4570-9AFE-A63D3D59DE0AQ38585916-16A4EE4D-7C4F-4BBF-BF7F-5634E1E6CC26Q38602633-F8BBA610-43CC-4B1F-8796-B2DFF4EB7B6CQ38762203-802D9266-6E90-4A59-9258-C9134758054EQ38762631-0476E719-8C0F-46B5-B3E3-860DBE872DE0Q38828713-80969797-68C1-4C71-BB2C-38BC079931AFQ38939695-737E783F-304D-428F-917E-4F32358341D8Q39170884-FDCC65AA-1DFF-4178-A251-D799E70E40DCQ39293427-35FED59A-0AA7-493A-AE15-23951F8A8792Q39423384-EC728EB3-E007-4028-B3D7-A92537122647Q39457369-845C56EA-9C3D-431C-BCF1-4D459FB22AB7Q40196834-5E035353-64B8-4337-963F-4FC677B1E193Q40296906-A8A9E8E5-5C45-4276-884D-62761AD77407Q42935464-50491659-48B1-4DAC-9E0D-393F4BDF060AQ43811918-98D999F6-508A-4D68-A9FB-B1370682D7E0Q44679459-3A8881CE-489C-463E-9EC5-EDC55E0A4FA8Q46446491-6722C4C4-CA51-45BC-A77F-9DAFEC51709C
P2860
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
@ast
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
@en
type
label
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
@ast
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
@en
prefLabel
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
@ast
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
@en
P2093
P2860
P1433
P1476
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.
@en
P2093
Hirofumi Teshima
Kenichi Sawada
Kensuke Usuki
Kunio Kitamura
Masahide Yamamoto
Naoto Takahashi
Noriko Usui
Shigeki Ohtake
Shinichiro Okamoto
Taiichi Kyo
P2860
P304
P356
10.3324/HAEMATOL.2011.056853
P577
2011-12-16T00:00:00Z